Analyst Reco. Adagene Inc.

Equities

ADAG

US0053291078

Delayed Nasdaq Other stock markets 10:25:23 2024-05-20 am EDT			5-day change	1st Jan Change
2.61 ^USD	+2.35%		+17.04%	+35.14%

Mar. 29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 29	Adagene Inc. Announces Board Changes	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Morgan Stanley Adjusts Price Target on Adagene to $5 From $7, Maintains Overweight Rating	23-01-24	MT
HC Wainwright Starts Adagene at Buy With $5 Price Target	22-12-07	MT
Morgan Stanley Cuts Price Target on Adagene to $7 From $15, Maintains Overweight Rating	22-09-09	MT
Berenberg Emerging Biotech Conference	22-05-18	FA
Morgan Stanley Adjusts Adagene's Price Target to $15 From $27, Reiterates Overweight Rating	22-02-01	MT
Morgan Stanley Adjusts Adagene's Price Target to $27 from $33, Keeps Overweight Rating	22-01-06	MT
ADAGENE : Morgan Stanley Adjusts Price Target on Adagene to $33 From $34, Maintains Overweight Rating	21-07-16	MT
ADAGENE : China Renaissance Starts Adagene at Buy With $40.57 Price Target	21-06-25	MT
ADAGENE : Morgan Stanley Starts Adagene at Overweight With $34 Price Target	21-03-08	MT
ADAGENE : Jefferies & Co Initiates Coverage on Adagene With Buy Rating, $33 Price Target	21-03-08	MT
ADAGENE : Goldman Sachs Initiates Coverage on Adagene With Buy Rating, $29 Price Target	21-03-08	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW